Oncopeptides

AGM Information • Apr 15, 2024

Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)

Stockholm, Sweden – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Monday, 15 April 2024. At the Extraordinary General Meeting, the following principal resolutions were passed.

• It was resolved, in accordance with the Board of Directors' proposal, to amend the articles of association whereby the share capital and the number of shares are increased. The purpose of the increase is to enable the proposed new issue of ordinary shares with preferential rights for the shareholders, in accordance with the below.
• It was resolved, in accordance with the Board of Directors' proposal, to approve the resolution by the Board of Directors on 13 March 2024, to increase the company's share capital through an issue of ordinary shares with preferential rights for the shareholders. According to the final terms set by the Board of Directors, as announced on 8 April 2024, each ordinary share in the company held on the record date for participation in the rights issue, 17 April 2024, entitles to one (1) subscription right and three (3) subscription rights entitle to subscription for four (4) new ordinary shares. The subscription price has been set to SEK 2.60 per ordinary share. The subscription period will run from 19 April 2024 up to and including 3 May 2024. Through the rights issue, the company's share capital can be increased by maximum SEK 13,398,463.766355 through the issuance of not more than 120,586,169 new ordinary shares. Additional information regarding the rights issue will be included in the prospectus which is expected to be published on or around the 17 April 2024.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ) E-mail: david.augustsson@oncopeptides.com Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com

Attachments

Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)